title: [PyNPase expression and cancer progression in the colorectum].
abstract: We analyzed PyNPase expression discriminating between cancer and tumor stroma of the colorectum by Western blotting using a newly developed extraction method from microdissected tissue sections fixed with buffered formalin. Analysis of 98 colorectal cancers revealed that PyNPase was as high as 70.2 +/- 18.5 unit/mg protein in the stroma fraction (SF), whereas it was 45.1 +/- 10.5 in the cancer fraction (CF) (p < 0.0001). Vessel density was correlated with PyNPase in the SF but not in the CF. In stage IIIb, 11 cases expressing a high level of PyNPase in the CF showed poorer prognosis than 10 cases with low-level PyNPase expression (p < 0.05), although the level of PyNPase expression in the SF did not affected the patients prognosis. Immunohistochemical examination indicated that PyNPase in the SF was mainly produced by macrophages (M phi), and therefore we investigated the profile of PyNPase production by M phi. In in vitro experiments PyNPase production by M phi was greatly enhanced by stimulation with OK-432, and the culture supernatant had the ability to convert 5'DFUR to 5-FU.
authors.affiliation: Department of Surgery, Osaka Teishin Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Monden
authors.forename: A
authors.initials: A
authors.lastname: Haba
authors.forename: M
authors.initials: M
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Kanoh
authors.forename: M
authors.initials: M
authors.lastname: Tsujie
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: H
authors.initials: H
authors.lastname: Izawa
authors.forename: T
authors.initials: T
authors.lastname: Ohnishi
authors.forename: M
authors.initials: M
authors.lastname: Sekimoro
authors.forename: N
authors.initials: N
authors.lastname: Tomita
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: M
authors.initials: M
authors.lastname: Monden
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D014408:Biomarkers, Tumor / Q000032:analysis; D015153:Blotting, Western; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D005467:Floxuridine / Q000493:pharmacokinetics; D006801:Humans; D008264:Macrophages / Q000378:metabolism; D010430:Pentosyltransferases / Q000032:analysis / Q000378:metabolism*; D011379:Prognosis; D057845:Pyrimidine Phosphorylases
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005467:Floxuridine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; C025034:doxifluridine